Karl Pappa, MD
Ophthalmology · Columbus, OHNPI 1760452338
Payments from drug & device makers
Across 129 payments — averaging $65.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$6K
- AbbVie$912
- Alcon$378
- Glaukos Corporation$310
- Biotissue Holdings Inc.$129
- Sun Pharmaceutical Industries Inc.$116
- plus $547 from 12 others
What the payments were for
- Speaking & faculty fees$5,74268%
- Food & beverage$2,70832%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 14 | $6,059 |
| AbbVie(2 entities) | 58 | $912 |
| Alcon | 6 | $378 |
| Glaukos Corporation | 8 | $310 |
| Biotissue Holdings Inc. | 5 | $129 |
| Sun Pharmaceutical Industries Inc. | 6 | $116 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $86 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $76 |
| Bausch & Lomb Americas Inc. | 4 | $76 |
| Novartis | 4 | $71 |
| Kala Pharmaceuticals, Inc. | 5 | $68 |
| Harrow Eye, LLC | 2 | $54 |
| Mallinckrodt Hospital Products Inc. | 1 | $34 |
| Ocular Therapeutix, Inc. | 2 | $29 |
| Oyster Point Pharma, Inc. | 1 | $17 |
| NEW World Medical,inc. | 1 | $14 |
| Thea Pharma Inc. | 1 | $14 |
| Beaver-visitec International, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$5,888
- Rocklatan$5,888
- Clareon PanOptix Pro$143
- Clareon$122
How this compares
$8,450 in reported general payments places this provider in the 85th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 192 | $94,732 |
| RocklatanNetarsudil Mesylat/Latanoprost | 174 | $81,311 |
| CombiganBrimonidine Tartrate/Timolol | 142 | $47,207 |
| RestasisCyclosporine | 42 | $42,457 |
| XiidraLifitegrast | 32 | $39,380 |
| RhopressaNetarsudil Mesylate | 65 | $28,735 |
| Timolol Maleate | 1,339 | $23,469 |
| Latanoprost | 2,628 | $20,734 |
| Prednisolone Acetate | 582 | $17,465 |
| VyzultaLatanoprostene Bunod | 40 | $16,868 |
| Travoprost | 83 | $13,760 |
| Alphagan PBrimonidine Tartrate | 50 | $12,816 |
| Cyclosporine | 23 | $11,004 |
| Brimonidine Tartrate | 456 | $10,048 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 77 | $9,895 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $912 | $197,212426 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $6,059 | $110,045239 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $76 | $56,24872 claims |
| AlconSimbrinza | $378 | $5,49621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Columbus
- David RogersColumbus$1.5M
- Alice EpitropoulosColumbus$702K
- Steven KatzColumbus$256K
- David LehmannColumbus$58K
- Lisa BorkowskiColumbus$25K
- John PajkaLima$17.7M
- Justis EhlersCleveland$5M
- Lawrence SingermanBeachwood$3.9M
- Sunil SrivastavaCleveland$2.8M
- Daniel MillerCincinnati$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.